Gilead’s Comparative Analysis To Bolster Remdesivir Draws Criticism

Gilead says remdesivir improved mortality and clinical recovery in COVID-19 patients, but the findings come from a retrospective analysis, not a traditional clinical trial.

Coronavirus globe
Gilead's retrospective analysis of remdesivir needs to be backed up by a traditional study

More from COVID-19

More from Scrip